Deutsche Bank Ag\ X4 Pharmaceuticals, Inc Transaction History

Deutsche Bank Ag\

$240 Billion
Q3 2024

A detailed history of Deutsche Bank Ag\ transactions in X4 Pharmaceuticals, Inc stock. As of the latest transaction made, Deutsche Bank Ag\ holds 40,577 shares of XFOR stock, worth $13,796. This represents 0.0% of its overall portfolio holdings.

Number of Shares

40,577

Previous 40,577 -0.0%

Holding current value

$13,796

Previous $23,000 17.39%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$0.58 - $1.47 $7,082 - $17,951	-12,212 Reduced 23.13%	40,577 $23,000
Q1 2024 May 15, 2024	BUY	$0.72 - $1.46 $38,008 - $77,071	52,789 New	52,789 $73,000
Q2 2023 Aug 14, 2023	BUY	$0.82 - $2.49 $50,206 - $152,455	61,227 New	61,227 $118,000
Q2 2021 Aug 11, 2021	SELL	$6.49 - $9.56 $67,749 - $99,796	-10,439 Closed	0 $0
Q1 2021 May 13, 2021	SELL	$6.63 - $10.28 $6,444 - $9,992	-972 Reduced 8.52%	10,439 $89,000
Q4 2020 Feb 16, 2021	BUY	$5.41 - $7.4 $17,522 - $23,968	3,239 Added 39.64%	11,411 $73,000
Q3 2020 Nov 12, 2020	BUY	$6.09 - $9.15 $3,483 - $5,233	572 Added 7.53%	8,172 $55,000
Q2 2020 Aug 13, 2020	BUY	$7.98 - $10.44 $16,143 - $21,120	2,023 Added 36.27%	7,600 $71,000
Q1 2020 May 14, 2020	SELL	$6.03 - $11.01 $11,149 - $20,357	-1,849 Reduced 24.9%	5,577 $56,000
Q4 2019 Feb 14, 2020	BUY	$9.93 - $14.33 $35,738 - $51,573	3,599 Added 94.04%	7,426 $78,000
Q3 2019 Nov 14, 2019	SELL	$11.06 - $15.75 $15,981 - $22,758	-1,445 Reduced 27.41%	3,827 $47,000
Q2 2019 Aug 14, 2019	BUY	$12.57 - $21.67 $15,322 - $26,415	1,219 Added 30.08%	5,272 $78,000
Q1 2019 May 15, 2019	BUY	$15.19 - $22.98 $61,565 - $93,137	4,053 New	4,053 $69,000

Others Institutions Holding XFOR

# of Institutions

105

Shares Held

100M

Call Options Held

213K

Put Options Held

50.6K

View Full List

About X4 Pharmaceuticals, Inc

Ticker XFOR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,646,096
Market Cap $23.3M
Description
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase...

More about XFOR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.

Account